EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Yoshiyuki Miyazawa, Takanori Shimizu, Yoshitaka Sekine, Seiji Arai, Akira Ohtsu, Yuji Fujizuka, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki

IJU Case Reports · 2023-01 · 6 (1) · 37-40

DOI: 10.1002/iju5.12543 ↗
AbstractBibliografische Angaben

Abstract

Introduction Several prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum‐based therapy can be used to predict the efficacy of poly(adenosine diphosphate‐ribose) polymerase inhibitors such as olaparib. Case presentation We experienced two neuroendocrine prostate cancer patients who achieved a response duration of more than 1 year with platinum‐based therapy. Case 1 had a BRCA2 mutation in the germline and case 2 had a BRCA2 mutation in a somatic chromosome only. Both patients responded well to olaparib. Conclusion Cisplatin and olaparib may overlap in response due to their medicinal action. It may be useful to consider genetic testing in some CRPC patients who have responded to cisplatin.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →